The addition of a MEK inhibitor to docetaxel demonstrated improved outcome in patients with KRAS-mutant NSCLC compared to either single agent treatment, combination with erlotinib, or docetaxel alone53. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.